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Paul S. Teirstein, MD,* Eric J. Topol, MD,*† for the GIFT Investigators
La Jolla, California; and Jacksonville, Florida
Objectives This study sought to evaluate the influence of single nucleotide polymorphisms (SNPs) on the pharmacodynamic
effect of high- or standard-dose clopidogrel after percutaneous coronary intervention (PCI).
Background There is a lack of prospective, multicenter data regarding the effect of different genetic variants on clopidogrel
pharmacodynamics over time in patients undergoing PCI.
Methods The GRAVITAS (Gauging Responsiveness with A VerifyNow assay–Impact on Thrombosis And Safety) trial
screened patients with platelet function testing after PCI and randomly assigned those with high on-treatment
reactivity (OTR) to either high- or standard-dose clopidogrel; a cohort of patients without high OTR were also fol-
lowed. DNA samples obtained from 1,028 patients were genotyped for 41 SNPs in 17 genes related to platelet
reactivity. After adjusting for clinical characteristics, the associations between the SNPs and OTR using linear
regression were evaluated.
Results CYP2C19*2 was significantly associated with OTR at 12 to 24 h (R2  0.07, p  2.2  1015), 30 days (R2 
0.10, p  1.3  107), and 6 months after PCI (R2  0.07, p  1.9  1011), whereas PON1, ABCB1 3435
C¡T, and other candidate SNPs were not. Carriers of 1 and 2 reduced-function CYP2C19 alleles were signifi-
cantly more likely to display persistently high OTR at 30 days and 6 months, irrespective of treatment assign-
ment. The portion of the risk of persistently high OTR at 30 days attributable to reduced-function CYP2C19 allele
carriage was 5.2% in the patients randomly assigned to high-dose clopidogrel.
Conclusions CYP2C19, but not PON1 or ABCB1, is a significant determinant of the pharmacodynamic effects of clopidogrel,
both early and late after PCI. In patients with high OTR identified by platelet function testing, the CYP2C19 geno-
type provides limited incremental information regarding the risk of persistently high reactivity with clopidogrel
150-mg maintenance dosing. (Genotype Information and Functional Testing Study [GIFT]; NCT00992420)
(J Am Coll Cardiol 2012;59:1928–37) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.068Clopidogrel, in combination with aspirin, reduces the risk of
cardiovascular events in patients with acute coronary syn-
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May 29, 2012:1928–37 The GIFT Studynetics and pharmacodynamics of clopidogrel vary widely
among individuals (4–7). Single-center studies using a
candidate gene approach have identified associations be-
tween reduced-function variants of the cytochrome 450
(CYP) 2C19 isozyme and on-treatment reactivity (OTR)
while receiving clopidogrel (8–13), and a genome-wide asso-
ciation study identified the reduced-function CYP2C19*2 allele
as the major determinant of adenosine diphosphate–induced
platelet aggregation in healthy Amish subjects treated with
clopidogrel (14). These findings are consistent with a 2-step
oxidative process required for transformation of clopidogrel
to its labile active metabolite, in which CYP2C19 contributes
substantially to each step (15). Candidate gene studies have
also detected associations between other single nucleotide
polymorphisms (SNPs) and clopidogrel pharmacodynamics
and outcomes after PCI, in particular the 3435 C¡T poly-
orphism of the ABCB1 gene that encodes the intestinal efflux
ransporter P-glycoprotein (16–18), and the Q192R polymor-
hism of the PON1 gene that encodes the esterase
araoxonase-1 (19). The latter observation has led to a sug-
ested alternative pathway of clopidogrel active metabolite
ormation that does not significantly involve CYP2C19, chal-
enging the mechanistic basis underlying the association be-
ween reduced-function CYP2C19 allele carriage and clinical
utcomes in ACS and PCI patients treated with clopidogrel
18,20–24). However, the clinical impact of the ABCB1 and
ON1 polymorphisms on clopidogrel efficacy has been incon-
istent (25,26), and therefore their effect on clopidogrel phar-
acodynamics in patients undergoing PCI requires further
alidation.
A higher clopidogrel maintenance dose (MD) could poten-
ially provide a more intense antiplatelet effect in patients with
genetic predisposition to a diminished response to standard-
ose therapy by providing greater substrate for biotransforma-
ion into the active metabolite. However, the relationships
etween common genetic polymorphisms and clopidogrel
harmacodynamics using different dosing strategies have not
een examined in the setting of a large clinical trial of patients
ndergoing PCI, where this antiplatelet drug is mostly used.
he objective of the current study was to assess the genetic
eterminants of clopidogrel response variability during the
cute and maintenance phases of therapy in a multicenter,
andomized, double-blind trial of high-dose compared with
tandard-dose clopidogrel after PCI.
ethods
tudy population. Patients were enrolled as part of a
re-specified genetic substudy of the GRAVITAS (Gaug-
ng Responsiveness with A VerifyNow assay–Impact on
hrombosis And Safety) trial. The study design, entry
riteria, baseline characteristics, and primary results of this
rial were described previously (27,28). The GRAVITAS
rial was a prospective, multinational, multicenter, double-
lind, randomized, active-controlled trial. Patients with
table coronary artery disease or ACS who had undergone 1CI with at least 1 drug-eluting
tent and on a specified peripro-
edural clopidogrel dosing regi-
en underwent platelet function
ssessment with the VerifyNow
2Y12 test 12 to 24 h after PCI.
atients with high on-treatment
latelet reactivity, defined as
230 P2Y12 reaction units
PRU), were randomly assigned by
n interactive voice response sys-
em to treatment with high-dose
lopidogrel (600 mg loading dose
ollowed by a 150-mg MD) or
tandard-dose clopidogrel (no ad-
itional loading dose, 75-mg
D). A randomly selected cohort of patients with OTR230
RU were selected by the interactive voice response system to
e followed in a blinded fashion and treated with a 75-mg MD
f clopidogrel, and the remainder exited the study after platelet
unction testing per protocol. In those treated with study drug,
latelet function was reassessed in a blinded fashion 30  7
ays and 180  14 days after enrollment.
The genetic substudy was conducted at 48 participating
ites, was approved by all institutional review boards, and
ritten informed consent was obtained from all partici-
ants. All patients who were entered into the GRAVITAS
rial interactive voice response system were eligible to be
nrolled in the genetic substudy. A total of 1,170 patients
onsented and provided blood samples for genotyping either
t the time of screening platelet function assessment 12 to
4 h after PCI or during follow-up (Fig. 1). Patients were
xcluded from the analysis if they were not of Caucasian
ncestry (self-identified) to avoid potential effects of popu-
ation stratification.
enotype analysis. Forty-three SNPs of 17 genes related
o platelet reactivity and/or previously implicated for having
n effect on clopidogrel responsiveness were genotyped
sing the MassARRAY platform (Sequenom, San Diego,
alifornia). Polymerase chain reaction assays and extension
rimers for these SNPs were designed using the Mass
RRAY design software, version 3.1. SNPs were genotyped
sing the iPLEX Gold assay (Sequenom, Inc., San Diego,
alifornia), based on multiplex polymerase chain reaction,
ollowed by a single base primer extension reaction. The
asses of the primer extension products correlating with
enotype were determined using matrix-assisted laser de-
orption/ionization time-of-flight mass spectroscopy. Final
enotypes were called using the MassARRAY Typer, ver-
ion 4.0. Seven samples were removed due to low call rates
sample call cutoff 90%). The mean call rate across the 43
NPs was 99.6% (range, 93.3% to 100%). Hardy-Weinberg
quilibrium was tested in a cohort of 611 patients who
onsented and had their genetic sample drawn at screening
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CI  confidence interval
CYP  cytochrome 450
MD  maintenance dose
OTR  on-treatment
reactivity
PCI  percutaneous
coronary artery
PRU  P2Y12 reaction unit
SNP  single nucleotide
polymorphism2 to 24 h after PCI (i.e., patients who were and were not
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The GIFT Study May 29, 2012:1928–37selected to be followed on study drug) because the distri-
bution of OTR in this cohort should better reflect the
general PCI population. Equilibrium was observed for 41 of
the 43 SNPs, and therefore these were included in subse-
quent analyses (Table 1).
Endpoints. The primary pharmacodynamic endpoint was
TR. Pre-specified analyses included the relationship be-
ween SNPs and OTR at screening 12 to 24 h after PCI and
t 30-day and 6-month follow-up; the change in OTR from
creening to 30 days; and the rate of high OTR, defined as
230 PRU. The primary efficacy endpoint was a composite
f death from cardiovascular causes, nonfatal myocardial
nfarction, or stent thrombosis. A clinical events committee
linded to treatment assignment and genotype and inde-
endent of the sponsor adjudicated all suspected primary
fficacy end points, as previously described (28).
tatistical analyses. SNPs were tested for their association
ith OTR by linear regression using a codominant model
285 high-dose 
clopidogrel
578 with High On-Treatment 
Reactivity (PRU  230) 
Randomized to: 
293 standard-dose 
clopidogrel
272 with platelet function 
assessment at 30-days
275 with platelet functi
assessment at 30-days
260 with platelet function 
assessment at 6-months
264 with platelet functi
assessment at 6-mont
142 excluded 
94 non-Caucasian ethnicity 
9 ethnicity unknown 
 7 with low call rate 
26 unable to process specimen  
1 major protocol deviation 
1,028 patients with plate
at randomization 1
1,170 patients with sam
Figure 1 Patient Flow
Patient flow in the study from enrollment through follow-up. PCI  percutaneous cfter adjusting for clinical characteristics associated with vOTR at an   0.05 level. These covariates were deter-
ined separately for the analyses of OTR at the time of
andomization (12 to 24 h after PCI) and at 30 days;
-month analyses used the same covariates as at 30 days.
onferroni-adjusted p value cutoffs were used to determine
tatistical significance. Associations between the 41 geno-
yped SNPs and on-treatment platelet reactivity were thus
valuated at the   0.0012 level of significance (i.e.,
.05  41). Multivariate generalized linear regression mod-
els were built for significant polymorphisms that included
relevant clinical characteristics as fixed covariates. The
specific portion of variance explained by genotype and
clinical characteristics were determined by calculating the
partial 2 from this model. The population-attributable risk
f persistently high reactivity was determined by subtracting
he incidence of high reactivity at 30 days in noncarriers from
he incidence in carriers and noncarriers combined. Categorical
ariables are reported as counts (percentages) and continuous
450 without High On-Treatment 
Reactivity (PRU <230) 
Allocated to: 
163 standard-dose 
clopidogrel
287 exited per study 
protocol
155 with platelet-function 
assessment at 30-days
149 with platelet function 
assessment at 6-months
nction assessment 
 hrs after PCI  
for genetic analysis 
Analysis population 
12-24 hrs after PCI 
Analysis population 
at 30-days 
Analysis population 
at 6-months 
y intervention; PRU  P2Y12 reaction unit.on 
on 
hs 
let fu
2 -24
ples 
oronarariables as mean SD where appropriate. Because this was a
o
w ltiple co
corona
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May 29, 2012:1928–37 The GIFT Studysubstudy, a target sample size was not pre-specified. The
sample size that was achieved provided 90% power to detect an
effect size (f2) of 0.021 and 80% power to detect an effect size
of 0.017 with   0.001. Analyses were performed with SAS
version 9.2 (SAS Institute Inc., Cary, North Carolina). The
sponsors had no role in the collection, management, analysis,
or interpretation of the data or in the preparation, review, or
Candidate SNPs, Their Frequencies, and Their Associations With Oat 12 to 24 h, 30 Days, and 6 Months After PCI*Table 1 Candidate SNPs, Their Frequencies, and Their Associaat 12 to 24 h, 30 Days, and 6 Months After PCI*
SNP Allele Allelic Frequency† R2
rs4244285 CYP2C19*2 0.15 0.065
rs7254579 CYP2B6*1B 0.32 0.013
rs4803418 CYP2B6*1C 0.30 0.007
rs4803419 CYP2B6*1C 0.30 0.006
rs12248560 CYP2C19*17 0.23 0.005
rs11264579 PEAR1 0.20 0.003
rs5918 ITGB3 0.15 0.003
rs12410842 VAV3/NTNG1 0.07 0.003
rs2769668 VAV3 0.07 0.003
rs17786144 ITPR1 0.13 0.003
rs8192719 CYP2B6*9 0.24 0.002
rs3745274 CYP2B6*6 0.23 0.002
rs1045642 ABCB1 3435C¡T 0.47 0.002
rs41299597 PEAR1 0.03 0.002
rs822442 PEAR1 0.11 0.002
rs5746223 RAF1 0.10 0.002
rs662 PON1 Q192R 0.31 0.002
rs41273215 PEAR1 0.10 0.002
rs350916 MAP2K2 0.46 0.002
rs17228705 PDGFC 0.16 0.001
rs3737224 PEAR1 0.10 0.001
rs6450105 ITGA1/ITGA2 0.27 0.001
rs6785930 P2RY12 0.30 0.001
rs41291556 CYP2C19*8 0.002 0.001
rs1128503 ABCB1 1236C¡T 0.44 0.001
rs41305896 ITGA2/ITGA1 0.025 0.001
rs168753 F2R (PAR-1) 0.16 0.001
rs16846673 P2RY12 0.002 0.001
rs2290159 RAF1 0.20 0.001
rs3729931 RAF1 0.35 0.001
rs776746 CYP3A5*3 0.07 0.001
rs17041401 ITPR1 0.41 0.001
rs28365083 CYP3A5*2A 0.01 0.001
rs28399504 CYP2C19*4 0.002 0.001
rs4986893 CYP2C19*3 0.008 0.001
rs851007 MAPK14 0.48 0.001
rs956115 IRS-1 0.08 0.001
rs72552267 CYP2C19*6 0§ 0.001
rs56337013 CYP2C19*5 0 NA
rs72558186 CYP2C19*7 0 NA
rs45593941 CYP3A5*3F 0 NA
*R2 values are adjusted for clinical covariates and at 30 days and 6 months for treatment assignm
btained at the time of platelet function assessment after PCI and before study drug assignment o
as determined a priori as the level at which to determine statistical significance to correct for mu
NA  not available because no carriers of the given allele were identified; PCI  percutaneousapproval of this paper.Results
A total 1,170 patients provided DNA samples over the
course of the study, of which 1,028 were included in the
analysis of OTR 12 to 24 h after PCI (Fig. 1). Their mean
age was 65.3  10.5 years, 301 patients (29.3%) were
women, 286 patients (27.8%) had diabetes mellitus, 118
atment ReactivityWith On-Treatment Reactivity
On-Treatment Reactivity
CI At 30 Days At 6 Months
p Value‡ R2 p Value‡ R2 p Value‡
.2  1015 0.104 1.3  1017 0.071 1.9  1011
0.0017 0.002 0.56 0.006 0.12
0.02 0.001 0.74 0.003 0.37
0.04 0.002 0.58 0.002 0.51
0.08 0.022 0.0004 0.015 0.01
0.21 0.004 0.24 0.009 0.06
0.21 0.013 0.01 0.008 0.07
0.23 0.002 0.54 0.005 0.17
0.23 0.002 0.54 0.005 0.17
0.24 0.002 0.44 0.001 0.90
0.30 0.005 0.18 0.003 0.34
0.33 0.005 0.19 0.003 0.33
0.32 0.001 0.97 0.002 0.49
0.34 0.002 0.44 0.009 0.05
0.39 0.001 0.73 0.001 0.92
0.42 0.001 0.99 0.001 0.81
0.42 0.001 0.61 0.001 0.69
0.45 0.001 0.75 0.001 0.99
0.45 0.001 0.92 0.001 0.85
0.51 0.001 0.77 0.001 0.93
0.53 0.001 0.69 0.001 1.00
0.27 0.001 0.44 0.001 0.88
0.58 0.007 0.08 0.007 0.08
0.32 0.003 0.14 0.005 0.07
0.61 0.004 0.29 0.003 0.36
0.39 0.001 0.41 0.001 0.94
0.71 0.003 0.32 0.001 0.71
0.45 0.001 0.80 0.001 0.89
0.94 0.002 0.56 0.002 0.58
0.96 0.002 0.53 0.001 0.83
0.90 0.001 0.83 0.003 0.38
0.92 0.006 0.13 0.002 0.57
0.50 0.001 0.87 0.003 0.16
0.91 0.002 0.29 0.001 0.53
0.77 NA NA NA NA
0.99 0.001 0.71 0.001 0.74
0.98 0.007 0.07 0.001 0.92
0.91 0.001 0.41 0.001 0.47
NA NA NA NA NA
NA NA NA NA NA
NA NA NA NA NA
Allelic frequencies were obtained from the cohort of 611 patients in whom genetic samples were
exit to avoid bias due to the study design. See Methods for more details. ‡A cutoff of p  0.0012
mparisons. §No carriers were present in the population enrolled at screening 12 to 24 h after PCI.
ry intervention; SNP  single nucleotide polymorphism.n-Tretions
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The GIFT Study May 29, 2012:1928–37displayed normal OTR. A total of 741 patients were
assigned to and followed on the study drug: 285 patients
displayed high OTR and were randomly assigned to high-
dose clopidogrel, 293 patients displayed high OTR and
were randomly assigned to standard-dose clopdiogrel, and
157 patients displayed normal OTR and were treated with
standard-dose clopidogrel. Repeat platelet function assess-
ment on the study drug was available at 30 days in 702
patients (95%) and at 6 months in 672 patients (91%).
Genetic determinants of OTR after PCI. Table 1 shows
the relationships between the candidate SNPs and OTR 12
to 24 h after PCI adjusted for clinical covariates significantly
associated with OTR according to univariate analysis (age,
sex, body mass index, current smoking, creatinine clearance
60 ml/min, diabetes mellitus, history of congestive heart
failure, hypertension, or hyperlipidemia). The CYP2C19*2
reduced-function allele was significantly associated with
OTR (R2  0.07, p  2.2  1015), whereas the PON1
Q192R, ABCB1 3435 C¡T, and CYP2C19*17 alleles were
not (R2 0.002, p 0.42; R2 0.001, p 0.97; and R2
0.005, p  0.08, respectively). There was a strong trend for
an association between the CYP2B6*1B allele and OTR
R2  0.013, p  0.0017). No interaction was observed
between the CYP2C19 and CYP2B6 genotypes (p  0.11).
Carriers of reduced-function CYP2C19 alleles present in
he study population (i.e., *2, *3, *4, *6, and *8) were pooled
or further analyses. Compared with noncarriers, the risk of
igh OTR 12 to 24 h after PCI was 2.5-fold greater for
arriers of 1 reduced-function CYP2C19 allele and approx-
mately 4.5-fold greater for carriers of 2 reduced-function
YP2C19 alleles (Fig. 2).
enetic determinants of OTR during follow-up. The
YP2C19*2 allele was significantly associated with OTR at
0 days (R2  0.10, p  1.3  1017) and at 6 months
R2  0.07, p  1.9  1011). Carriage of PON1 Q192R
and ABCB1 3435 C¡T were not associated with OTR at
30 days or 6 months; an association between CYP2C19*17
carriage and reduced levels of OTR became apparent at 30
days (R2 0.022, p 0.0004), although the association did
not reach the threshold of significance at 6 months (R2 
0.015, p  0.01) (Table 1). Body mass index, diabetes
ellitus, age, and current smoking also contributed signif-
cantly to the variance in OTR at both time points in the
ultivariate model incorporating the CYP2C19 genotype
(Table 2).
Clopidogrel MD strategy, CYP2C19 genotype, and
OTR. Figure 3 shows the change in OTR from random-
ization to 30 days according to treatment arm stratified by
the CYP2C19 genotype. After adjustment for treatment
ssignment, characteristics significantly associated with the
hange in reactivity from randomization to 30 days on
ultivariate analysis were CYP2C19 genotype (2  0.054,
 0.0001), age (2  0.02, p  0.001), and body mass
index (2  0.006, p  0.032).
CYP2C19 reduced-function allele carriage was associatedwith a substantially greater risk of high OTR at 30 days and6 months, particularly for carriers of 2 reduced-function
alleles, irrespective of maintenance dosing strategy (Fig. 4).
Among the patients with high OTR after PCI who were
randomly assigned to clopidogrel 150-mg MD, the portion
of the risk of persistently high reactivity attributable to
reduced-function allele carriage (population-attributable
0.1 1 10 30
Odds Ratio (95% CI)
Odds Ratio
(95% CI)
CYP2C19 Reduced-FunctionAlleles,
No. of Patients/
No. of Patients at Risk
200/288 346/691 2.52 (1.86-3.43)
23/29 346/691 4.71 (1.83-12.14)
Increased Risk
in Noncarriers
Increased Risk
in Carriers
1 None
2 None
A
At Randomization
223/317 346/691 2.66 (1.97-3.58)
1 or 2 None
0.1 1 10 30
Odds Ratio (95% CI)
Odds Ratio
(95% CI)
CYP2C19 Reduced-FunctionAlleles,
No. of Patients/
No. of Patients at Risk
128/235 158/445 2.29 (1.59-3.30)
17/21 158/445 9.51 (2.86-31.63)
Increased Risk
in Noncarriers
Increased Risk
in Carriers
1 None
2 None
B
At 30 Days
145/256 158/445 2.51 (1.76-3.59)
1 or 2 None
0.1 1 10 30
Odds Ratio (95% CI)
Odds Ratio
(95% CI)
CYP2C19 Reduced-FunctionAlleles,
No. of Patients/
No. of Patients at Risk
111/220 130/420 2.56 (1.75-3.74)
16/21 130/420 9.49 (3.01-29.93)
Increased Risk
in Noncarriers
Increased Risk
in Carriers
1 None
2 None
C
At 6 Months
128/256 130/420 2.80 (1.93-4.07)
1 or 2 None
Figure 2 Adjusted Odds Ratios for High On-Treatment
Reactivity by CYP2C19 Genotype
At randomization (A), at 30 days (B), and at 6 months (C). Odd ratios are ver-
sus noncarriers, adjusted for clinical covariates at randomization and for clini-
cal covariates and treatment arm at 30 days and 6 months. The number of
patients with high on-treatment reactivity and the total number of patients at
risk of high on-treatment reactivity are presented for each comparison. The p
values for trend are 0.0001 for the CYP2C19 genotype and the risk of high
on-treatment reactivity for all time points. Patient numbers may vary due to the
lack of complete data for multivariate analysis in some patients. CI  confi-
dence interval.risk) was 5.2%. The population-attributable risk was 7.3%
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May 29, 2012:1928–37 The GIFT Studyusing a cut point of PRU 208 for persistently high
eactivity. The CYP2C19 genotype was also significantly
associated with a greater risk of persistently high reactivity
during follow-up among the patients with high OTR
randomly assigned to standard-dose clopidogrel (p 
0.0002) (Fig. 4).
Clinical outcomes. The primary clinical endpoint of death
due to cardiovascular causes, nonfatal myocardial infarction,
or stent thrombosis occurred in 14 patients (1.9%) during
follow-up. Carriers of 2 reduced-function alleles were at
significantly higher risk of the primary endpoint compared
with noncarriers (1 event in 24 patients at-risk compared
with 11 events in 466 patients at-risk; hazard ratio: 1.58;
95% confidence interval [CI]: 1.04 to 2.41; p  0.03).
There was no association between carriage of 1 reduced-
function CYP2C19 allele and the primary endpoint (2 events
in 244 patients at risk; hazard ratio: 1.07; 95% CI: 0.91 to
1.25; p  0.42). There was no association between PON1
Q192R carriage and clinical outcomes (carriers of 1 allele
compared with noncarriers: odds ratio: 0.97; 95% CI: 0.83
to 1.14; p  0.73; carriers of 2 alleles compared with
noncarriers: odds ratio: 0.90; 95% CI: 0.69 to 1.17; p 
0.44).
Discussion
In this prospective substudy of a large, randomized, multi-
center clinical trial, we tested the association between OTR
and several gene variants that plausibly could be related to
interindividual variability in adenosine diphosphate–
induced platelet reactivity in patients treated with clopi-
dogrel, including those encoding the CYP450 enzyme
family, cell surface receptors, kinases, and other signaling
Full Multivariate Generalized Linear Models of Oat 30 Days and 6 Months After PCITable 2 Full Multiv riate Gene alized Linearat 30 Days and 6 Months After PCI
Characteristic
3
Partial 2*
Study arm 0.150
CYP2C19 genotype† 0.097
Body mass index 0.0183
Diabetes mellitus 0.0123
History of congestive heart failure 0.0127
Age 0.0094
Creatinine clearance 60 ml/min 0.0077
Current smoking 0.0065
Calcium channel blocker use 0.0049
History of hyperlipidemia 0.0028
Bivalirudin use during index PCI 0.0015
Proton pump inhibitor use 0.0009
ACS presentation 0.0001
Sex 0.0001
UFH use during index PCI 0.0001
*2 is the specific portion of variance explained by the characteristic
alleles.
ACS  acute coronary syndrome(s); PCI  percutaneous coronary imolecules (29). This study provides strong evidence that: c1) CYP2C19 is a key genetic determinant of OTR while
receiving clopidogrel early and late after PCI; 2) identifica-
tion of the CYP2C19 genotype in patients with high OTR
according to platelet function testing provides only limited
information regarding the risk of persistently high reactivity
with clopidogrel 150-mg MD; and 3) it is unlikely that PON1
or ABCB1 contributes significantly to clopidogrel response
variability and, by extension, to clopidogrel metabolism.
Despite the clinical risk that appears to be imparted by
the CYP2C19 genotype in PCI patients treated with clopi-
dogrel (21,22), the pharmacodynamic effect of CYP2C19
among this patient population has not been previously
examined in a prospective, multicenter setting. Our finding
of a very robust association between the CYP2C19 genotype
and OTR is strengthened by several factors: the moderate-
to-large effect size (R2 between 0.065 and 0.10 during
ollow-up, adjusted odds ratios 2.5 for high OTR in
arriers of at least 1 reduced-function allele); the magnitude
f the p value (1 1010); statistical correction for multiple
omparisons; and the low likelihood of population stratifica-
ion given the homogeneous ethnicity of the analysis cohort.
e thereby avoided common pitfalls of candidate gene studies
hat can lead to false-positive reporting. We believe that these
esults provide definitive evidence supporting a pharmacody-
amic basis for the reported association between CYP2C19 and
ardiovascular outcomes. Our findings that, after adjustment
or clinical and procedural characteristics, reduced-function
YP2C19 allele carriage explains approximately 10% of clopi-
ogrel response variability in the long-term phase of therapy at
0 days and 7% at 6 months extend previous observations of a
imilar contribution in the acute setting (14,30), and supports
he continued influence of CYP2C19 on clopidogrel pharma-
atment Reactivityels of On-Treatment Reactivity
s 6 Months
p Value Partial 2* p Value
0.0001 0.125 0.0001
0.0001 0.069 0.0001
0.0004 0.010 0.011
0.0037 0.0080 0.0227
0.0031 0.0092 0.0149
0.0112 0.0105 0.0092
0.0215 0.0037 0.1204
0.0344 0.0085 0.0190
0.0672 0.0049 0.0759
0.1673 0.0018 0.2787
0.3125 0.0001 0.8866
0.4453 0.0017 0.2923
0.7662 0.0006 0.5278
0.9504 0.0001 0.8041
0.8793 0.0001 0.8569
C19 genotype was classified according to 0, 1, or 2 loss-of-function
tion; UFH  unfractionated heparin.n-TreMod
0 Day
. †CYP2odynamics over time.
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The GIFT Study May 29, 2012:1928–37In the GRAVITAS trial, high-dose clopidogrel com-
pared with standard-dose clopidogrel did not reduce the
incidence of cardiovascular events among patients with high
OTR after PCI (28). An insufficient pharmacodynamic
response may have contributed in part to the lack of clinical
effectiveness observed with high-dose therapy (31). The
current study demonstrates that among patients with high
OTR according to platelet function testing after PCI,
CYP2C19 is a key determinant of a persistently heightened
level of OTR with a standard clopidogrel MD and a
diminished antiplatelet effect with a high clopidogrel MD.
However, in patients randomly assigned to the 150-mg MD
of clopidogrel, the portion of the risk of persistently high
OTR at 30 days attributable to reduced-function allele
carriage was only 5% using the pre-specified definition of
high reactivity (230 PRU) and only 7% using a post hoc
definition (208 PRU) that has been associated with
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Figure 3
Change in On-Treatment Reactivity From
Randomization to 30 Days by CYP2C19 Genotype
and Treatment Group
Unadjusted (A) and adjusted (B) for clinical covariates. In the group of
patients without high on-treatment reactivity followed on standard-dose clopi-
dogrel, only 1 patient was a carrier of 2 reduced-function CYP2C19 alleles and
is not included. Central markers denote the mean, and error bars the SDs. p
Values are corrected for multiple comparisons using the Bonferroni method.
LOF  loss of function.subsequent cardiovascular events (31). rThe association that we observed between the
CYP2C19*17 allele and an increased antiplatelet effect of
clopidogrel was inconsistent, with a significant relationship
noted at 30 days but not reaching the threshold for
significance after PCI or at 6-month follow-up. Although
some observational studies have shown increased platelet
inhibition in carriers of the so-called gain-of-function
CYP2C19*17 allele (32,33), other studies have shown no
effect (14,21,34–36). The findings of clinical outcome
studies are similarly inconsistent (18,25,32,37,38). The
comparative strength of the association of CYP2C19*2 in
our cohort further supports the supposition that reduced-
function alleles play the dominant genetic role in determin-
ing on-clopidogrel platelet reactivity (36), and, by extension,
in influencing clinical outcomes.
We investigated the influence of polymorphisms of the
ABCB1 gene, which encodes the P-glycoprotein efflux trans-
porter believed to mediate the intestinal absorption of clopi-
dogrel (16). Data regarding the effect of the ABCB1 3435
C¡T polymorphism on clopidogrel pharmacodynamics is
imited and inconsistent (14,17,35,36). The impact of the
BCB1 genotype on clinical outcomes after PCI has also been
iscordant between studies (17,18,25). In the present study,
one of the common polymorphisms of ABCB1, including
435 C¡T, influenced OTR after PCI, at 30 days, or at 6
onths, thereby challenging the biological plausibility of an
ffect of the ABCB1 genotype on clinical outcomes in
lopidogrel-treated patients in the acute or maintenance
hases.
We assessed the influence of PON1, which encodes the
aroxonase-1 enzyme that has been proposed to mediate
he rate-limiting step in clopidogrel metabolism (19). A
ase-cohort and replication study observed that the
ON1 Q192R polymorphism was associated with lower
araoxonase-1 plasma activity, lower active metabolite lev-
ls, lower platelet inhibition, and a 10-fold greater risk of
tent thrombosis in PCI patients receiving clopidogrel
19). We did not detect any influence of PON1 Q192R
n the antiplatelet effect of clopidogrel, either in the
cute or chronic phase of therapy after PCI. Therefore,
ccording to our findings, there does not appear to be a
harmacodynamic basis for a clinical effect of PON1 on
ardiovascular outcomes in clopidogrel-treated patients.
retrospective case-cohort study also did not confirm an
ffect of PON1 Q192R in patients with stent thrombosis
26), and a retrospective, post hoc single-center study of
lective PCI patients also did not observe a relationship
etween the PON1 genotype and the effect of clopidogrel on
esidual platelet aggregation by light transmittance aggregom-
try (39).
linical implications. On-treatment reactivity while re-
eiving clopidogrel has been associated with clinical out-
omes in a patient-level meta-analysis and in a pharmaco-
ynamic analysis of the GRAVITAS trial (31,40). The
ndings of the current study have several implications
egarding optimal antiplatelet therapy after PCI. The
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May 29, 2012:1928–37 The GIFT StudyCYP2C19 genotype is predictive of high OTR in both the
early and late phases after PCI. Carriers of 2 reduced-
function CYP2C19 alleles are highly likely to display levels
of OTR associated with adverse outcomes, and a 150-mg
MD of clopidogrel had a particularly marginal pharmaco-
dynamic effect in these patients. Therefore, in patients who
are identified to be poor metabolizers by genotyping, the use
of alternative P2Y12 antagonists that are not influenced by
YP2C19 should be considered if an adequate pharmaco-
ynamic effect is desired. In patients who have undergone
latelet function testing and are thereby determined to be at
igher risk of ischemic events, additional CYP2C19 geno-
yping provides little help in identifying who will adequately
espond to a 150-mg MD of clopidogrel. Whether even
arger doses of clopidogrel may provide an improved re-
ponse in reduced-function CYP2C19 allele carriers is being
examined in the ELEVATE–TIMI 56 (Escalating Clopi-
dogrel by Involving a Genetic Strategy–Thrombolysis In
Myocardial Infarction 56) trial (NCT01235351).
Study limitations. A potential limitation of the present
study is that the GRAVITAS trial, by design, preferentially
enrolled patients with higher levels of OTR. This selection
bias potentially reduced the power of our association tests.
Procedural characteristics and concomitant medications,
0.1 1 10 100
Odds Ratio (95% CI)
Odds Ratio
(95% CI)
CYP2C19 Reduced-FunctionAlleles,
No. of Patients/
No. of Patients at Risk
42/96 55/166 1.63 (0.93-2.88)
7/9 55/166 11.53 (2.08-64.07)
Increased Risk
in Noncarriers
Increased Risk
in Carriers
1 None
2 None
A High-dose clopidogrel, 30 days
49/105 55/166 1.88 (1.09-3.25)
1 or 2 None
0.1 1 10 100
Odds Ratio (95% CI)
Odds Ratio
(95% CI)
CYP2C19 Reduced-FunctionAlleles,
No. of Patients/
No. of Patients at Risk
72/98 90/165 2.66 (1.47-4.82)
10/11 90/165 10.57 (1.19-93.88)
Increased Risk
in Noncarriers
Increased Risk
in Carriers
1 None
2 None
C Standard-dose clopidogrel, 30 days
82/109 90/165 2.92 (1.63-5.24)
1 or 2 None
Figure 4 Adjusted Odds Ratios for High On-Treatment Reactivit
CYP2C19 Genotype According to Maintenance Dose
Odds ratios are versus noncarriers and are adjusted for clinical covariates. (A)
(B) High-dose clopidogrel at 6 months; p trend  0.003. (C) Standard-dose clopidogr
0.0002. Patient numbers may vary due to the lack of complete data for multivariate aincluding proton pump inhibitor use, were not available forthe entire cohort at randomization, but were available and
included in the adjusted analyses at follow-up. We did not
examine the pharmacodynamic effect of CYP2C19 on dif-
ferent clopidogrel loading doses, although our findings are
consistent with those reported by a single-center case-
control study (41). The study was not powered to detect the
influence of genotype on clinical events, and the significant
association between carriage of 2 reduced-function CYP2C19
alleles and outcomes must be considered exploratory and
hypothesis generating, although it is consistent with previous
reports (18,21,22).
Conclusions
The findings of this pharmacogenetic analysis of a multicenter,
randomized clinical trial demonstrate a strong and consistent
association between the CYP2C19 genotype and OTR while
receiving clopidogrel after PCI, present during both the early
and long-term phases after the procedure and irrespective of
MD. In patients with high OTR identified by platelet function
testing, the CYP2C19 genotype provides only limited incre-
mental information regarding the risk of persistently high
reactivity with a treatment strategy of clopidogrel 150 mg daily.
0.1 1 10 100
Odds Ratio (95% CI)
Odds Ratio
(95% CI)
P2C19 Reduced-FunctionAlleles,
No. of Patients/
No. of Patients at Risk
34/89 44/113 1.77 (0.96-3.25)
6/9 44/113 11.45 (2.29-57.23)
Increased Risk
in Noncarriers
Increased Risk
in Carriers
1 None
2 None
High-dose clopidogrel, 6 Months
40/98 44/113 2.03 (1.13-3.66)
1 or 2 None
0.1 1 10 100
Odds Ratio (95% CI)
Odds Ratio
(95% CI)
P2C19 Reduced-FunctionAlleles,
No. of Patients/
No. of Patients at Risk
63/91 76/156 2.48 (1.38-4.45)
10/11 76/156 12.54 (1.48-107.19)
Increased Risk
in Noncarriers
Increased Risk
in Carriers
1 None
2 None
Standard-dose clopidogrel, 6 Months
73/102 76/156 2.80 (1.58-4.97)
1 or 2 None
30 Days and 6 Months by
nment
ose clopidogrel MD at 30 days; p trend  0.004 for the CYP2C19 genotype.
0 days; p trend  0.0002. (D) Standard-dose clopdiogrel at 6 months; p trend 
in some patients. CI  confidence interval; MD  maintenance dose.CY
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n clopidogrel-treated patients.
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